NASDAQ:VTVT vTv Therapeutics Q3 2026 Earnings Date & Estimates $31.18 +1.10 (+3.66%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$31.14 -0.04 (-0.11%) As of 10/9/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. vTv Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateNovember 6, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from vTv Therapeutics in Q3 2026vTv Therapeutics is expected to post earnings of -$1.16 per share on revenue of $0.33 million. In the same quarter a year earlier vTv Therapeutics reported -$1.08 per share. vTv Therapeutics last reported on August 6, 2026, posting -$1.05 per share and missing the -$0.97 consensus estimate. vTv Therapeutics has beaten the consensus EPS estimate in 3 of its last 7 quarters.Consensus EstimatesConsensus EPS-$1.16Expected Revenue$0.33 millionPrior-Year EPS-$1.08Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.05 (Missed by -$0.08)EPS Beat Rate3 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report vTv Therapeutics Q3 2026 Earnings FAQ When does vTv Therapeutics report Q3 2026 earnings? vTv Therapeutics (NASDAQ:VTVT) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is vTv Therapeutics' Q3 2026 earnings call? vTv Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for vTv Therapeutics? Analysts expect vTv Therapeutics to post earnings of -$1.16 per share for Q3 2026. How much revenue is vTv Therapeutics expected to report? The consensus revenue estimate for vTv Therapeutics is $0.33 million for Q3 2026. vTv Therapeutics Earnings HeadlinesvTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026October 10 at 8:54 AM | markets.businessinsider.comvTv Therapeutics stock jumps on FDA orphan drug statusOctober 8 at 4:49 PM | uk.finance.yahoo.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Analysts Conflicted on These Healthcare Names: vTv Therapeutics (VTVT) and CSL (OtherCMXHF)October 8 at 6:47 AM | theglobeandmail.comVTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell DiseaseOctober 8 at 6:47 AM | rttnews.comContrasting Milestone Pharmaceuticals (NASDAQ:MIST) and vTv Therapeutics (NASDAQ:VTVT)October 8 at 2:15 AM | americanbankingnews.comSee More vTv Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like vTv Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on vTv Therapeutics and other key companies, straight to your email. Email Address About vTv TherapeuticsvTv Therapeutics (NASDAQ:VTVT), Inc. (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease. vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease. The company has also investigated other compounds targeting metabolic pathways, including oral treatments that may influence glucose regulation and appetite. Based in the United States, vTv conducts development activities through clinical research and collaborations intended to advance its drug candidates toward potential commercialization. Its products remain investigational and are subject to clinical testing and regulatory review; the company does not currently market an approved therapy.View vTv Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
